SCHEMBL30559677

SCHEMBL30559677

O=C(O)CCc1c(C(=O)O)[nH]c2cc(Cl)cc(Cl)c12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
GPR17 Q13304 14/20 1.00
FBP1 P09467 1/20 1.00
GRIN1 Q05586 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8463078 1.00 GPR17 (1.00) GPR17FBP1GRIN1
SCHEMBL13956651 0.86 GPR17 (0.76) GPR17FBP1
SCHEMBL266498 0.82 GPR17 (0.70) GPR17FBP1GRIN1
SCHEMBL9433429 0.81 GPR17 (0.68) GPR17FBP1GRIN1
SCHEMBL28421067 0.80 GPR17 (0.67) GPR17FBP1GRIN1
SCHEMBL14739207 0.80 GPR17 (1.00) GPR17FBP1
SCHEMBL15463511 0.80 GPR17 (0.66) GPR17FBP1GRIN1
SCHEMBL9078111 0.79 GPR17 (0.64) GPR17FBP1GRIN1
SCHEMBL9432682 0.79 GRIN1 (0.71) GPR17FBP1GRIN1
SCHEMBL9076074 0.77 GPR17 (0.61) GPR17FBP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034138-A1 NOVEL PYRIMIDINYL AND TRIAZINYL SULFONAMIDE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2026-02-05 US disclosed
US-20250188061-A1 NOVEL DEUTERATED PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2025-06-12 US disclosed
CN-119731168-A Deuterated pyrimidin-2-ylsulfonamide derivatives 豪夫迈·罗氏有限公司 2025-03-28 CN disclosed
CN-119585258-A Novel 7-substituted indole sulfonamide derivatives 豪夫迈·罗氏有限公司 2025-03-07 CN disclosed
CN-119585257-A Novel 7-substituted indole sulfonamide derivatives 豪夫迈·罗氏有限公司 2025-03-07 CN disclosed
CN-119562950-A Novel pyrimidinyl and triazinyl sulfonamide derivatives 豪夫迈·罗氏有限公司 2025-03-04 CN disclosed
CN-119546576-A Novel isoquinolinones pyrrolo-pyridones and thieno pyridone sulfonamide derivatives 豪夫迈·罗氏有限公司 2025-02-28 CN disclosed
CN-119546572-A Novel naphthyl and isoquinoline sulfonamide derivatives 豪夫迈·罗氏有限公司 2025-02-28 CN disclosed
CN-119546608-A Novel imidazopyridine and pyrazolopyridine sulfonamide derivatives 豪夫迈·罗氏有限公司 2025-02-28 CN disclosed
CN-116829550-A Pyrimidine-2-ylsulfonamide derivatives 豪夫迈·罗氏有限公司 2023-09-29 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250188061-A1 NOVEL DEUTERATED PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES DDX41, CDK2, CCNT2 GPR17 1413/4885FBP1 2853/4885GRIN1 480/4885
US-20260034138-A1 NOVEL PYRIMIDINYL AND TRIAZINYL SULFONAMIDE DERIVATIVES GPR180, GPR27, GPR17 GPR17 3/4885FBP1 4599/4885GRIN1 316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.